SequelSEC

Immunovant, Inc. IMVT

Biological Products, (No Diagnostic Substances) · CIK 0001764013 · Fiscal year ends 0331

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
Unavailable
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Immunovant, Inc. (IMVT) reported net income of -$153.22M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Immunovant, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Immunovant, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net income-$153.22M-$147.86M-$110.64MUnavailableUnavailable-$106.45M-$111.12MUnavailableUnavailable-$75.32M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 205.55MUnavailableshares 181.51MUnavailableUnavailableUnavailableshares 146.92MUnavailableUnavailableUnavailable
Pretax income-$153.22M-$150.70M-$109.08MUnavailableUnavailable-$105.87M-$110.97MUnavailableUnavailable-$75.09M
Income tax expense$0-$2.84M$1.55MUnavailableUnavailable$583.00K$152.00KUnavailableUnavailable$232.00K
Diluted EPS$-0.75Unavailable$-0.61UnavailableUnavailableUnavailable$-0.76UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$17.69M$17.27M$15.44MUnavailableUnavailable$20.17M$19.78MUnavailableUnavailable$14.82M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Immunovant, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$797.80M$902.11M$994.52MUnavailableUnavailable$713.97M$374.68MUnavailableUnavailable$635.36M
Total assets$852.49M$957.01M$1.05BUnavailableUnavailable$776.22M$420.93MUnavailableUnavailable$666.36M
Current assets$851.18M$948.82M$1.04BUnavailableUnavailable$767.66M$412.54MUnavailableUnavailable$665.77M
Total liabilities$117.10M$104.42M$66.26MUnavailableUnavailable$68.78M$68.32MUnavailableUnavailable$48.61M
Current liabilities$117.10M$104.42M$66.26MUnavailableUnavailable$68.78M$68.32MUnavailableUnavailable$48.61M
Total equity incl. NCI$735.39M$852.59M$986.14MUnavailableUnavailable$707.45M$352.62MUnavailableUnavailable$617.76M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$697.00K$1.13M$1.64MUnavailableUnavailable$2.08M$2.22MUnavailableUnavailable$5.34M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$10.14M$7.54M$8.62MUnavailableUnavailable$17.66M$19.82MUnavailableUnavailable$7.16M

Cash flow

Immunovant, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$124.40M-$95.06M-$92.32MUnavailableUnavailable-$110.64M-$100.39MUnavailableUnavailable-$59.70M
Capital expendituresUnavailable$8.00K$0UnavailableUnavailable$201.00K$180.00KUnavailableUnavailable$150.00K
Investing cash flowUnavailable-$8.00K$0UnavailableUnavailable-$201.00K-$180.00KUnavailableUnavailable-$150.00K
Financing cash flow$20.10M$3.64M$564.60MUnavailableUnavailable$450.61M$2.46MUnavailableUnavailable$1.54M
Net change in cash-$104.31M-$92.42M$472.66MUnavailableUnavailable$339.29M-$98.26MUnavailableUnavailable-$55.57M
Stock-based compensation$13.77M$11.14M$12.72MUnavailableUnavailable$11.69M$11.65MUnavailableUnavailable$9.68M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Immunovant, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailable-$95.07M-$92.32MUnavailableUnavailable-$110.84M-$100.57MUnavailableUnavailable-$59.85M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio7.27x9.09x15.74xUnavailableUnavailable11.16x6.04xUnavailableUnavailable13.70x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMVT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-K · Filed 2026-05-20View SEC filing
10-Q · Filed 2026-02-06View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-K · Filed 2025-05-29View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.